Literature DB >> 18753156

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.

Sonal Singh, Curt D Furberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18753156     DOI： 10.1136/hrt.2008.155507

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  3 in total

1.  Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease.

Authors:  Gyeong-Im Yu; Ho-Chan Cho; Yun-Kyeong Cho; Hyoung-Seob Park; Hyuck-Jun Yoon; Hyung-Seop Kim; Chang-Wook Nam; Yoon-Nyun Kim; Kwon-Bae Kim; Eunyoung Ha; Dong-Hoon Shin; Seung-Ho Hur
Journal:  Inflamm Res       Date:  2012-05-17       Impact factor: 4.575

2.  Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells.

Authors:  Clintoria R Williams; Xianghuai Lu; Roy L Sutliff; C Michael Hart
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-09       Impact factor: 4.249

3.  Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.

Authors:  Jan O Friedrich; Joseph Beyene; Neill K J Adhikari
Journal:  BMC Res Notes       Date:  2009-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.